CurrentBlue Cross Blue Shield - TexasPolicy CPCPLAB049

General Inflammation Testing (CRP and ESR) Reimbursement Policy

Governs reimbursement criteria for measurement of CRP and ESR (including high-sensitivity CRP) for specified diagnosed or suspected inflammatory conditions under Blue Cross and Blue Shield of Texas products; affects providers submitting claims for these lab tests.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyGeneral Inflammation Testing (CRP and ESR) Reimbursement Policy

Policy CodePolicy CPCPLAB049

Change TypeMaterial revisions and code addition

Effective DateNov 7, 2025

Next Review DateN/A

Key ActionSubmit accurate documentation and HIPAA-approved code combinations; claims are subject to claim review and may require additional documentation upon request.

SourceLink

POLICY UPDATE CHANGES

Added Note referencing CPCPLAB046 for the use of CRP as a marker for acute pancreatitis.

Removed the word 'inflammatory' from #1 because some listed conditions are noninflammatory.

Revised Table 1 introduction to specify test preferences, allow conventional or high-sensitivity CRP, prefer CRP when either allowed, and allow only CRP when both ordered for a condition where either is allowed.

Within Table 1, modified entries for Irritable Bowel Syndrome and Large Vessel Vasculitis (added Giant Cell Arteritis and Takayasu Arteritis and their frequencies), deleted a row specific to Giant Cell Arteritis, and adjusted frequencies.

Added procedure code 86141 to the policy's code list.

Table 1Table of conditions

CPCPLAB049Policy ID

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria for CRP and ESR

Condition-specific coverage rules (selected examples)

Measurement of CRP and/or ESR may be reimbursable when the conditions and frequencies noted below are met. Exceptions: ESR is not reimbursable for individuals without a diagnosed inflammatory condition; measurement of CRP and/or ESR during a general exam without abnormal findings is not reimbursable. Either conventional or high-sensitivity CRP methods are allowed. When either CRP or ESR are allowed, CRP is preferred; if both are ordered where only one is allowed, only CRP will be allowed.

Selected condition-specific rules

Acute and Chronic Urticaria: Test preference = CRP or ESR; Frequency = Not specified.
Acute Hematogenous Osteomyelitis (AHO): Test preference = CRP; Frequency = To confirm diagnosis; 2-3 days during the early therapeutic course; weekly until normalization or a clear trend toward normalization is evident.
Acute Phase Inflammation: Test preference = CRP; Frequency = Not specified.
Arthritis: Test preference = CRP and ESR; Frequency = Regular interval use in patients with active symptoms: 1-3 months initially; 6-12 months later (prior to treatment; every 1-3 months during active disease; annually when disease is inactive).
Castleman's Disease: Test preference = CRP or ESR; Frequency = Not specified.
General Inflammation: Test preference = CRP; Frequency = Not specified.
Hodgkin Lymphoma: Test preference = ESR; Frequency = Every 3-6 months for 1-2 years; every 6-12 months for the next 3 years; annually thereafter.
Irritable Bowel Syndrome: Test preference = CRP and ESR; Frequency = During initial assessment to exclude other diagnoses (e.g., inflammatory bowel disease).
Large Vessel Vasculitis (Giant Cell Arteritis, Takayasu Arteritis): Test preference = CRP and ESR; Frequency = To confirm diagnosis; every 1-3 months during the first year; every 3-6 months thereafter.
Nonradiographic axial spondyloarthritis: Test preference = CRP or ESR; Frequency = Regular interval use in patients with active symptoms.
Polymyalgia Rheumatica: Test preference = CRP or ESR; Frequency = At initial diagnosis; every 3 months during long-term steroid therapy.
Periprosthetic Joint Infections (PJI): Test preference = CRP and ESR; Frequency = Not specified.
Rheumatoid Arthritis: Test preference = CRP or ESR; Frequency = Prior to treatment; every 1-3 months during active disease; annually when disease is inactive.
Systemic Lupus Erythematosus: Test preference = CRP or ESR; Frequency = At initial assessment; every 1-3 months during active disease; every 6-12 months during stable disease; during pregnancy.
T-cell Lymphomas: Test preference = ESR; Frequency = Not specified.

Operational notes

Either conventional CRP or high-sensitivity CRP (hsCRP) methods are allowed for CRP testing.
When either CRP or ESR are allowed, CRP is the preferred biomarker; if both CRP and ESR are ordered for a condition where CRP or ESR are allowed, only CRP will be allowed.
ESR is not reimbursable for individuals without a diagnosed inflammatory condition; testing during a general exam without abnormal findings is not reimbursable.

Procedure codes and coding rules

Example procedure codes (not exhaustive)CPT

86141

C-reactive protein (CRP) — added to policy code list

Testing preference and restriction

Policy testing preference and restrictionWhen either CRP or ESR are allowed, CRP is the preferred biomarker; if CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP will be allowed.

Exception for individuals without diagnosed inflammatory conditionMeasurement of ESR is not reimbursable for individuals without a diagnosed inflammatory condition.

General exam limitationMeasurement of CRP and/or ESR during a general exam without abnormal findings is not reimbursable.

Reference to related biomarker policiesSee CPCPLAB046 for CRP as a cardiac biomarker and CPCPLAB04Z for CRP in acute pancreatitis.

Provider documentation and claims requirements

Documentation Required

Submit accurate documentation and expect claim review

Providers must submit accurate documentation of services and use correct code combinations from HIPAA‑approved code sets. Claims are subject to claim review including benefit coverage terms, provider contract language, medical policies, clinical payment and coding policies, and coding software logic; providers should submit any additional documentation upon request.

Use HIPAA‑approved code sets and industry standard coding guidelines when coding claims.
Be prepared to provide medical records or other supporting documentation if requested during claim review.

Test methods and coverage designation definitions

CRP methods

Allowed CRP methodsEither conventional CRP or high-sensitivity CRP (hsCRP) testing are allowed methods for measuring CRP levels.

Preferred marker when both allowedWhen either CRP or ESR are allowed, CRP is the preferred biomarker.

Restriction when both orderedIf CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP will be allowed.

Table 1 coverage designations

Meaning of designations in Table 1Table 1 designates for each condition whether CRP, ESR, CRP or ESR, or both CRP and ESR are appropriate and provides frequency guidance where specified.

Preferred biomarker guidanceWhen either CRP or ESR are allowed for a condition, CRP is preferred.